Patents by Inventor Thomas McDonagh

Thomas McDonagh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SirT inhibitors that bind to NAD
    Patent number: 8486990
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: July 16, 2013
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • SirT Inhibitors That Bind to NAD
    Publication number: 20090306168
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 14, 2009
    Publication date: December 10, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • N-TRADD active site and uses thereof
    Patent number: 7460961
    Abstract: The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein (“N-TRADD”), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provided for by the present invention are methods of utilizing the three dimensional structures for the design and selection of potent and selective inhibitors of TNF signaling pathways.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: December 2, 2008
    Assignee: Genetics Institute, LLC
    Inventors: Desiree H. H. Tsao, Jean-Baptiste Telliez, Thomas McDonagh, Lih-Ling Lin, Sang Hsu, Guang-Yi Xu, A. Karl Malakian
  • AGGRECANASE STRUCTURE
    Publication number: 20070178574
    Abstract: This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.
    Type: Application
    Filed: August 24, 2006
    Publication date: August 2, 2007
    Applicant: WYETH
    Inventors: Lydia Mosyak, Thomas Rush, Xiaotian Zhong, Thomas McDonagh, Katy Georgiadis, Phaik-Eng Sum, Edward LaVallie, Lisa Collins-Racie, Christopher Corcoran, Ravindra Kumar, Tracy Hebert, Stephane Olland, Stewart Mackie
  • Substrate detection assay
    Publication number: 20060292652
    Abstract: Methods and compositions for evaluating nicotinamide-releasing activities as well as cell and organism-based evaluation methods are provided herein.
    Type: Application
    Filed: July 13, 2005
    Publication date: December 28, 2006
    Inventors: Rory Curtis, Andrew Napper, Jeffrey Hixon, Thomas McDonagh
  • Modified ADAMTS4 molecules and method of use thereof
    Publication number: 20060228354
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Application
    Filed: June 12, 2006
    Publication date: October 12, 2006
    Applicant: Wyeth
    Inventors: Christopher Corcoran, Carl Flannery, Weilan Zeng, Lisa Racie, Thomas McDonagh, Bethany Freeman, Katy Georgiadis, Edward LaVallie
  • Modified ADAMTS4 molecules and method of use thereof
    Patent number: 7118902
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: October 10, 2006
    Assignee: Wyeth
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • Methods of treating a disorder
    Publication number: 20060074124
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: March 11, 2005
    Publication date: April 6, 2006
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Methods of treating a disorder
    Publication number: 20050250794
    Abstract: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I) (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: December 20, 2004
    Publication date: November 10, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh
  • Methods of treating a disorder
    Publication number: 20050209300
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: September 13, 2004
    Publication date: September 22, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • N-TRADD active site and uses thereof
    Publication number: 20050002898
    Abstract: The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein (“N-TRADD”), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provided for by the present invention are methods of utilizing the three dimensional structures for the design and selection of potent and selective inhibitors of TNF signaling pathways.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 6, 2005
    Inventors: Desiree Tsao, Jean-Baptiste Telliez, Thomas McDonagh, Lih-Ling Lin, Sang Hsu, Guang-Yi Xu, A. Malakian
  • Modified ADAMTS4 molecules and method of use thereof
    Publication number: 20040142863
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Application
    Filed: July 29, 2003
    Publication date: July 22, 2004
    Applicant: WYETH
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • N-TRADD active site and uses thereof
    Publication number: 20020094540
    Abstract: The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein (“N-TRADD”), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provided for by the present invention are methods of utilizing the three dimensional structures for the design and selection of potent and selective inhibitors of TNF signaling pathways.
    Type: Application
    Filed: March 29, 2001
    Publication date: July 18, 2002
    Inventors: Desiree H.H. Tsao, Jean-Baptiste Telliez, Thomas McDonagh, Lih-Ling Lin, Sang Hsu, Guang-Yi Xu, A. Karl Malakian